Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.
about
Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studiesRole of endothelin in cardiovascular diseaseVascular endothelin receptor type B: structure, function and dysregulation in vascular diseaseEndothelin receptor antagonists and cerebral vasospasm: an update.Angiotensin II receptor blockade unmasks a depressor response to endothelin antagonists in rats.Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.Endothelin in heart failure.Recent advances in the management of chronic heart failure.New and emerging pharmacologic strategies in the management of chronic heart failure.The role of endothelin receptor antagonists in the treatment of chronic heart failure.Novel therapeutics for the treatment of paediatric pulmonary arterial hypertension.The therapeutic potential of endothelin receptor antagonists in cardiovascular disease.Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.Endothelin antagonists and heart failure.Endothelin receptor antagonists in cardiology clinical trials.Present and future pharmacotherapy for heart failure.Bosentan: a dual endothelin receptor antagonist.Heart failure in 10 years time: focus on pharmacological treatment.The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system.Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin-1 in the control of pulmonary vascular toneThe rational use of diuretics in heart failure.Treatment of congestive heart failure a neuroendocrine disorder.Role of endothelins in congestive heart failure.Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart diseaseDirect comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure.Tezosentan in the treatment of acute heart failure.Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivoIs too much neurohormonal blockade harmful?Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management.Effect of bosentan on pulmonary hypertension secondary to systolic heart failure.Endothelins: pathophysiology and treatment implications in chronic heart failure.Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.Future pharmacologic agents for treatment of heart failure in children.The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth.Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?Cardiac Fibrosis: The Fibroblast AwakensEndothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization.Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy.Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
P2860
Q26746907-9A049C0D-D94D-46C7-9850-706D32B51A42Q28216230-18EF447A-9D57-498A-A67C-C017605B8660Q28263963-54EBA279-7BC1-4CA8-B447-FE0A8EE6420AQ30310232-106ED932-1711-4DA1-8556-DA4AD9235AACQ31355796-A0A4F6E4-6D77-4400-B893-67A78F3DD185Q33653672-7AD04BDE-493E-4FB1-A1D8-623E37712B2CQ34028140-60321F22-6C10-4B24-856E-B29FF37B4176Q34031741-DBA015CC-7D8B-4658-8B50-DCD1B90C6937Q34075359-CB3846EF-1DC0-405C-A5D3-76F0DF98D72FQ34221061-5F6A67EF-B45C-4E78-BE34-7120368687A4Q34232006-64CFB8AD-F36E-4EA7-8BC2-4867244DCEDBQ34317655-D588AFDC-6F9B-4A89-9E73-3CE68E980F6CQ34448373-47EF1CA4-8C97-4D28-967E-A66B0055E3B4Q34492848-0F69B876-5BE3-48D6-A69C-77A7019EDB9EQ34544685-86E70592-29D4-4E6C-9CCC-FD9875A78C88Q34706912-203B182B-2ED0-47D5-A62F-8BBA7324F4C0Q34707006-AA9B72B1-365F-4417-907C-FB60EB3FE649Q34817094-D57AA7A6-7C75-4423-B4AE-7F252CA0B7EFQ35001002-BF0580AB-05A7-4421-98EE-4DD845B8A4CEQ35044124-C6DC08C0-77A6-4DCB-B8C9-5672217DB4B2Q35105848-EA893CF3-F07A-47BA-B798-4CA2685A92EFQ35110636-F5A16AE1-8CA2-45DF-AC8B-78B59A86B88DQ35168419-04F6A006-6926-43F1-9A47-6CC07A04A3D5Q35581586-103FFCEA-02B5-4119-B9A2-669673EB3906Q35584359-CDBCB5D0-5FDC-48F5-828E-419CE49AEFF1Q35590982-26857361-6B9E-4AD3-B035-8E2899C57B0CQ35631333-CEE4AA2A-3B8F-4BA3-BA4F-4D8FE5FA7C1CQ35653851-548AE71E-8C82-49E2-A076-C6EB69FC400EQ35742253-0448F7BD-632C-4B49-A91E-3BC61F4D6276Q36013674-709B67EC-53A0-4DAE-A0F1-34FA04AE4C7DQ36302304-96B714CD-7CC6-4DE9-B979-248025617816Q36332869-7450B7DB-42A0-4702-AC44-F68E30DD3007Q36543145-A4026969-F0FE-48B1-8891-078505171D72Q36577692-371474AC-6939-47E7-B6B8-40962F1513AAQ36610320-B51E6BF9-4EED-47E2-B1AE-6802691A9AA9Q36674362-837E3B92-1B7B-4C9D-A3ED-881501BEF956Q36708340-28D17FC0-0207-43E7-AA45-0534D090BE26Q36717615-267D95C0-885B-4EE1-A42B-7F3569AF420AQ36814875-794BDF0B-6C1A-4690-9AEE-F3651A13B5A5Q36836706-99DEFF6A-633B-4F23-A813-514C5679301A
P2860
Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Short-term oral endothelin-rec ...... severe chronic heart failure.
@en
Short-term oral endothelin-rec ...... severe chronic heart failure.
@nl
type
label
Short-term oral endothelin-rec ...... severe chronic heart failure.
@en
Short-term oral endothelin-rec ...... severe chronic heart failure.
@nl
prefLabel
Short-term oral endothelin-rec ...... severe chronic heart failure.
@en
Short-term oral endothelin-rec ...... severe chronic heart failure.
@nl
P2093
P1433
P1476
Short-term oral endothelin-rec ...... severe chronic heart failure.
@en
P2093
P Hunziker
P Rickenbacher
S Christen
P304
P356
10.1161/01.CIR.98.21.2262
P407
P577
1998-11-01T00:00:00Z